Pre-treatment of the cells with proteasome inhibitor MG-132 prevented TGF- isoforms from decreasing PTEN protein content (Determine4B), showing that TGF–induced decrease of PTEN involves proteasome activity

Pre-treatment of the cells with proteasome inhibitor MG-132 prevented TGF- isoforms from decreasing PTEN protein content (Determine4B), showing that TGF–induced decrease of PTEN involves proteasome activity. samples from endometrial tumours was assessed using immunofluorescence. Two model cancer cell lines (KLE endometrial carcinoma cells and HeLa cervical cancer cells) and pharmacological inhibitors were used to investigate the signalling pathways regulating XIAP expression and activity in response to autocrine and paracrine TGF- in cancer cell. == Results == We have found immunoreactivity for each TGF- isoform in clinical samples from endometrial tumours, localizing to both stromal and epithelial/cancer cells. Blockade of autocrine TGF- signaling in KLE endometrial carcinoma cells and HeLa cervical cancer cells reduced endogenous XIAP mRNA and protein levels. In addition, each TGF- isoform upregulated XIAP gene expression when given exogenously, in a Smad/NF-B dependent manner. This resulted in increased polyubiquitination of PTEN (phosphatase and tensin homolog on chromosome ten), a newly identified substrate for XIAP E3 ligase activity, and in a XIAP-dependent decrease of PTEN protein levels. Although each TGF- isoform decreased PTEN content in a XIAP- and a Smad-dependent manner, decrease of PTEN levels in response to only one isoform, TGF-3, was blocked by PI3-K Darapladib inhibitor LY294002. == Conclusions == XIAP gene expression and function is usually positively regulated by exposure to the three TGF- isoforms in a Smad-dependent manner, similar to constitutive XIAP gene expression which depends on autocrine TGF-/Smad signalling. == Background == TGF- (transforming growth factor-beta) is usually a major regulator of proliferation, survival, migration/invasion and metastasis in cancer cells (reviewed in [1]). Upon ligand binding, TGF- receptor I (TGF-RI) recruits and phosphorylates Smad2 and Smad3: phosphorylated Smad2 or Smad3 then associate with Smad4 to form heterodimeric complexes that translocate to the nucleus, where they can induce downstream transcriptional responses [2]. Apart from this Darapladib canonical Smad signalling pathway, TGF-beta can also activate ERK [3] and PI3-K [4] pathways. Most data concerning TGF- signaling and function comes from studies focusing on TGF-1. However, three TGF- isoforms have been identified in mammalian cells: TGF-1, TGF-2 and TGF-3. The three TGF- isoforms can play redundant roles in cancer cells. Mouse monoclonal to ROR1 However, recent studies have shown that TGF- isoforms can differentially regulate cancer cell phenotype: Darapladib in prostate cancer Darapladib cells for example, TGF-2, but not TGF-1, confers resistance to TNF-induced apoptosis [5]. Similarly, TGF-3, but not TGF-1 or TGF-2, increase the invasiveness of endometrial carcinoma cells in vitro [6]. XIAP (X-linked inhibitor of apoptosis protein) plays a key antiapoptotic role in endometrial carcinoma cells. This member of the inhibitor of apoptosis protein family can directly inhibit caspases-3, -7, and -9 [6], and we recently observed that XIAP protects endometrial carcinoma cells against various proapoptotic agents, including TGF- [6], TNF [7] and chemotherapeutic drugs Darapladib [8]. We have recently reported that exposure to each of the three TGF- isoforms increase XIAP protein levels in endometrial carcinoma cells [6]. Our results suggested that TGF- isoforms differentially activate intracellular signaling pathways in endometrial carcinoma cell: indeed, only TGF-3 activates PI3-K/Akt pathway and increases XIAP protein levels in a PI3-K-dependent manner in these cells [6]. The different molecular mechanisms through which each TGF- isoform increases XIAP protein content thus remains to be decided. We have recently highlighted a new function for XIAP in cancer cells, in promoting polyubiquitination and proteasomal degradation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) [9]. PTEN is usually a critical tumour suppressor [10], which negatively regulates pro-survival PI3-K/Akt pathway through its lipid phosphatase activity [11], and inhibits several regulators of cell cycle progression, including MAPK superfamily member ERK, through its protein phosphatase activity [12]. XIAP-induced degradation of PTEN is usually thus one of the mechanisms through which cancer cells can achieve successful inactivation of PTEN tumour suppressor function. Cellular factors regulating XIAP-induced degradation of PTEN, however, remain to be identified. We have showed that TGF-3.